Showing results (51-60 of 85) with videos related to

Sort By:
Pageof 9
Scientific Reports|January 8, 2024
Effect of integrated hepatitis C virus treatment on psychological distress in people with substance use disordersChrister F Aas, Jørn Henrik Vold, Fatemeh Chalabianloo, et al.
BMC Psychiatry|December 11, 2012
Amphetamine-induced psychosis--a separate diagnostic entity or primary psychosis triggered in the vulnerable?Jørgen G Bramness, Øystein Hoel Gundersen, Joar Guterstam, et al.
Substance Abuse Treatment, Prevention, and Policy|April 24, 2023
The efficacy of integrated hepatitis C virus treatment in relieving fatigue in people who inject drugs: a randomized controlled trialJørn Henrik Vold, Fatemeh Chalabianloo, Else-Marie Løberg, et al.
Psychiatry Research|January 25, 2026
Levels of and changes in psychosis symptoms and clinical insight: Exploring the impact of differential antipsychotic mechanismsLena Antonsen Stabell, Erik Johnsen, Rune Kroken, et al.
Schizophrenia Research|July 17, 2012
Auditory verbal hallucinations in schizophrenia as aberrant lateralized speech perception: evidence from dichotic listeningKenneth Hugdahl, Else-Marie Løberg, Liv E Falkenberg, et al.
Substance Abuse Treatment, Prevention, and Policy|May 4, 2021
Subjective symptoms and serum methadone concentrations: what should guide dose adjustments in methadone maintenance treatment? A naturalistic cohort study from NorwayFatemeh Chalabianloo, Lars Thore Fadnes, Gudrun Høiseth, et al.
Schizophrenia Research|December 28, 2014
Glutamate as a mediating transmitter for auditory hallucinations in schizophrenia: a (1)H MRS studyKenneth Hugdahl, Alexander R Craven, Merethe Nygård, et al.
Psychiatry Research. Neuroimaging|June 2, 2020
Hallucinating schizophrenia patients have longer left arcuate fasciculus fiber tracks: a DTI tractography studyLiv E Falkenberg, René Westerhausen, Erik Johnsen, et al.
Substance Abuse Treatment, Prevention, and Policy|February 28, 2021
Substance use and symptoms of mental health disorders: a prospective cohort of patients with severe substance use disorders in NorwayChrister Frode Aas, Jørn Henrik Vold, Rolf Gjestad, et al.
General Hospital Psychiatry|June 3, 2023
Does drug use affect the efficacy of amisulpride, aripiprazole and olanzapine in patients with schizophrenia spectrum disorders? Results from a pragmatic, randomised studyRenata Alisauskiene, Erik Johnsen, Rolf Gjestad, et al.
Pageof 9